Ventyx Biosciences Inc (VTYX)

$14.00 +0.02 (0.14%)
Market Cap 1.00B
Revenue (ttm) 0.00
Net Income (ttm) -135.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,448,800
Avg Vol 4,041,894
Day's Range N/A - N/A
Shares Out 71.76M
Stochastic %K 100%
Beta 1.26
Analysts Hold
Price Target $13.44

Company Profile

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimo...

Industry: Biotechnology
Sector: Healthcare
Phone: 760-407-6511
Address:
12790 El Camino Real, Suite 200, San Diego, United States
TheRealShortSqueezy
TheRealShortSqueezy Sep. 3 at 12:12 PM
🚨 $MDCX : MAJOR PFIZER DEAL JUST DROPPED Medicus Pharma just entered into a Co-Development & License Agreement with Pfizer for CD228V, an early-stage antibody-drug conjugate targeting CD228. 🔹 Exclusive worldwide license to develop and commercialize CD228V 🔹 Pfizer remains involved in the program and is providing $2M in development funding 🔹 Pfizer has the option to fund all or part of development starting with the first pivotal trial 🔹 Medicus retains control over development, manufacturing, regulatory approval and commercialization 🔹 Agreement includes more than $1 BILLION in potential development, regulatory and sales milestones 🔹 Pfizer is also eligible for low double-digit royalties on future net sales This adds an entirely new oncology asset to the MDCX pipeline with Pfizer remaining directly involved in its development. SECTOR PEERS: $CRNX $ARQT $IMVT $VTYX
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 3 at 12:11 PM
$MDCX : MULTIPLE CATALYSTS LINING UP Medicus Pharma is a clinical stage biotech developing next-generation treatments for skin cancers and hormone related diseases, led by its SkinJect and Teverelix platforms. 🔹 SkinJect: FDA cleared its NDA enabling registrational study in Gorlin Syndrome. 🔹 Phase 2 data showed 64% clinical clearance 🔹 Teverelix: Phase 2 AUR trial optimized to roughly 126 patients vs. 390 previously planned following FDA feedback. 🔹 $25.2M in cash reported at June 30. 🔜 UPCOMING CATALYSTS • Initiation and enrollment of the SkinJect NDA-enabling registrational trial • Advancement of the Teverelix Phase 2 AUR program • Further development in high cardiovascular risk prostate cancer 💰 With SkinJect and Teverelix targeting multiple high value indications, MDCX is building a pipeline addressing an estimated $8 BILLION combined market opportunity. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyMDCX SECTOR PEERS: $CRMD $CRNX $ARQT $VTYX
0 · Reply
KingdomStock
KingdomStock Apr. 28 at 9:05 PM
$VTYX RSI: 68.75, MACD: 0.2678 Vol: 0.02, MA20: 13.96, MA50: 12.84 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
supertech1
supertech1 Mar. 9 at 2:27 PM
$VTYX what’s going on …should I get rid of it?
0 · Reply
stockbuyer1234
stockbuyer1234 Mar. 6 at 12:29 PM
$VTYX I still see the march call options on my Schwabb.Did they close the transaction?
4 · Reply
ians
ians Mar. 4 at 7:16 PM
$VTYX $VKTX CONGRATS to LT shareholders. 👍 LLY just knows how to pick em early. Wish we could have demanded more but mgmt had no bargaining power w/o a white knight in the form of SNY. 🤷‍♂️ Nonetheless, I was correct VTYX turned out to be the next VKTX. Just didn't think it would get taken out sooner than VKTX. The ? Now is which BP will BO VKTX & for how much 🤔☘️💎 https://stocktwits.com/ians/message/586903018
0 · Reply
Viktor4o
Viktor4o Mar. 4 at 12:38 PM
$VTYX How long its been halted for?
1 · Reply
NorthStarStats
NorthStarStats Mar. 4 at 10:52 AM
Market is full of failed breakout and rug pulls. Be careful. From the scanner: $IDYA Score: 98.00, $TGT Score: 73.00, $DAY Score: 70.00, $VTYX Score: 70, $RTX Score: 68.00
2 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Mar. 4 at 8:30 AM
$VTYX VTYX- ​Acquisition Approval: Shareholders officially approved the merger with Eli Lilly on March 3, 2026. ​Merger Details: Eli Lilly is acquiring VTYX for $14.00 per share in an all-cash deal. ​What Happens to the Stock: Once the merger is finalized (expected in the first half of 2026), VTYX will stop trading on the NASDAQ and become a wholly-owned subsidiary of Eli Lilly.
0 · Reply
Elevate1
Elevate1 Mar. 4 at 8:16 AM
$VTYX amazing the bulk is the shareholders approved with 44 million shareholders voting and only about 1.6 million voting against. I guess myself and my institutional friends will be all alone in our minority appraisal. Well we will be the only ones to share those benefits. It will be a while but will be lucrative. In the meantime Lly stock should be bought they now control the whole inflammatory cascade and NVO will now be cut in half from here in 6 months. PFE’s metsera purchase worth 90% less!
1 · Reply
Latest News on VTYX
Ventyx Biosciences, Inc. Investigated by the Portnoy Law Firm

Apr 29, 2026, 9:00 AM EDT - 4 months ago

Ventyx Biosciences, Inc. Investigated by the Portnoy Law Firm

Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights

Jan 21, 2026, 2:42 PM EST - 8 months ago

Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights

SNCY

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)

Jan 8, 2026, 11:44 AM EST - 8 months ago

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)

Pharma stocks are set to take off this year, says UBS' Michael Yee

Jan 8, 2026, 11:01 AM EST - 8 months ago

Pharma stocks are set to take off this year, says UBS' Michael Yee

IBB LLY

Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal

Jan 7, 2026, 4:25 PM EST - 8 months ago

Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal

LLY

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

Jan 7, 2026, 4:17 PM EST - 8 months ago

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

LLY

Lilly in talks to buy Ventyx Biosciences in more than $1 billion deal, WSJ reports

Jan 6, 2026, 3:48 PM EST - 8 months ago

Lilly in talks to buy Ventyx Biosciences in more than $1 billion deal, WSJ reports

LLY

Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter

Jan 6, 2026, 3:40 PM EST - 8 months ago

Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter

LLY

Ventyx Provides Clinical and Corporate Updates

Dec 2, 2025, 7:02 AM EST - 9 months ago

Ventyx Provides Clinical and Corporate Updates

Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:02 AM EST - 9 months ago

Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Nov 17, 2025, 7:02 AM EST - 10 months ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Nov 6, 2025, 4:02 PM EST - 10 months ago

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Oct 22, 2025, 4:02 PM EDT - 11 months ago

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Aug 27, 2025, 7:02 AM EDT - 1 year ago

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

May 8, 2025, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Feb 27, 2025, 4:05 PM EST - 1 year ago

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Feb 18, 2025, 8:00 AM EST - 1 year ago

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Jan 14, 2025, 8:00 AM EST - 1 year ago

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Sep 6, 2024, 8:00 AM EDT - 2 years ago

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Ventyx Biosciences Announces Departure of Chief Financial Officer

Aug 30, 2024, 8:00 AM EDT - 2 years ago

Ventyx Biosciences Announces Departure of Chief Financial Officer

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 2 years ago

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Aug 8, 2024, 4:01 PM EDT - 2 years ago

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

Jun 24, 2024, 6:00 AM EDT - 2 years ago

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

Jun 21, 2024, 4:15 PM EDT - 2 years ago

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

Jun 20, 2024, 7:20 AM EDT - 2 years ago

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

Jun 19, 2024, 4:20 PM EDT - 2 years ago

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

Jun 18, 2024, 3:42 PM EDT - 2 years ago

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 17, 2024, 6:32 AM EDT - 2 years ago

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 13, 2024, 4:06 PM EDT - 2 years ago

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm

Jun 13, 2024, 7:13 AM EDT - 2 years ago

VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm

STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading

Jun 12, 2024, 4:04 PM EDT - 2 years ago

STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading

VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors

Jun 11, 2024, 3:37 PM EDT - 2 years ago

VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors

VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board

Jun 11, 2024, 6:41 AM EDT - 2 years ago

VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board

TheRealShortSqueezy
TheRealShortSqueezy Sep. 3 at 12:12 PM
🚨 $MDCX : MAJOR PFIZER DEAL JUST DROPPED Medicus Pharma just entered into a Co-Development & License Agreement with Pfizer for CD228V, an early-stage antibody-drug conjugate targeting CD228. 🔹 Exclusive worldwide license to develop and commercialize CD228V 🔹 Pfizer remains involved in the program and is providing $2M in development funding 🔹 Pfizer has the option to fund all or part of development starting with the first pivotal trial 🔹 Medicus retains control over development, manufacturing, regulatory approval and commercialization 🔹 Agreement includes more than $1 BILLION in potential development, regulatory and sales milestones 🔹 Pfizer is also eligible for low double-digit royalties on future net sales This adds an entirely new oncology asset to the MDCX pipeline with Pfizer remaining directly involved in its development. SECTOR PEERS: $CRNX $ARQT $IMVT $VTYX
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 3 at 12:11 PM
$MDCX : MULTIPLE CATALYSTS LINING UP Medicus Pharma is a clinical stage biotech developing next-generation treatments for skin cancers and hormone related diseases, led by its SkinJect and Teverelix platforms. 🔹 SkinJect: FDA cleared its NDA enabling registrational study in Gorlin Syndrome. 🔹 Phase 2 data showed 64% clinical clearance 🔹 Teverelix: Phase 2 AUR trial optimized to roughly 126 patients vs. 390 previously planned following FDA feedback. 🔹 $25.2M in cash reported at June 30. 🔜 UPCOMING CATALYSTS • Initiation and enrollment of the SkinJect NDA-enabling registrational trial • Advancement of the Teverelix Phase 2 AUR program • Further development in high cardiovascular risk prostate cancer 💰 With SkinJect and Teverelix targeting multiple high value indications, MDCX is building a pipeline addressing an estimated $8 BILLION combined market opportunity. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyMDCX SECTOR PEERS: $CRMD $CRNX $ARQT $VTYX
0 · Reply
KingdomStock
KingdomStock Apr. 28 at 9:05 PM
$VTYX RSI: 68.75, MACD: 0.2678 Vol: 0.02, MA20: 13.96, MA50: 12.84 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
supertech1
supertech1 Mar. 9 at 2:27 PM
$VTYX what’s going on …should I get rid of it?
0 · Reply
stockbuyer1234
stockbuyer1234 Mar. 6 at 12:29 PM
$VTYX I still see the march call options on my Schwabb.Did they close the transaction?
4 · Reply
ians
ians Mar. 4 at 7:16 PM
$VTYX $VKTX CONGRATS to LT shareholders. 👍 LLY just knows how to pick em early. Wish we could have demanded more but mgmt had no bargaining power w/o a white knight in the form of SNY. 🤷‍♂️ Nonetheless, I was correct VTYX turned out to be the next VKTX. Just didn't think it would get taken out sooner than VKTX. The ? Now is which BP will BO VKTX & for how much 🤔☘️💎 https://stocktwits.com/ians/message/586903018
0 · Reply
Viktor4o
Viktor4o Mar. 4 at 12:38 PM
$VTYX How long its been halted for?
1 · Reply
NorthStarStats
NorthStarStats Mar. 4 at 10:52 AM
Market is full of failed breakout and rug pulls. Be careful. From the scanner: $IDYA Score: 98.00, $TGT Score: 73.00, $DAY Score: 70.00, $VTYX Score: 70, $RTX Score: 68.00
2 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Mar. 4 at 8:30 AM
$VTYX VTYX- ​Acquisition Approval: Shareholders officially approved the merger with Eli Lilly on March 3, 2026. ​Merger Details: Eli Lilly is acquiring VTYX for $14.00 per share in an all-cash deal. ​What Happens to the Stock: Once the merger is finalized (expected in the first half of 2026), VTYX will stop trading on the NASDAQ and become a wholly-owned subsidiary of Eli Lilly.
0 · Reply
Elevate1
Elevate1 Mar. 4 at 8:16 AM
$VTYX amazing the bulk is the shareholders approved with 44 million shareholders voting and only about 1.6 million voting against. I guess myself and my institutional friends will be all alone in our minority appraisal. Well we will be the only ones to share those benefits. It will be a while but will be lucrative. In the meantime Lly stock should be bought they now control the whole inflammatory cascade and NVO will now be cut in half from here in 6 months. PFE’s metsera purchase worth 90% less!
1 · Reply
Viktor4o
Viktor4o Mar. 3 at 10:42 PM
$VTYX Sad news, I was expecting higher bid 😕
2 · Reply
TwongStocks
TwongStocks Mar. 3 at 10:14 PM
$VTYX With shareholders approving the merger, today will be the last day of trading. Expect NASDAQ to halt trading in VTYX at 7:50pm ET tonight 👇
1 · Reply
petr2022
petr2022 Mar. 3 at 10:13 PM
$VTYX Approved overwhelmingly.
1 · Reply